Eloralintide (LY3841136) is an investigational, long-acting synthetic analog of human amylin designed to preferentially activate the amylin 1 receptor (AMY1R). It is studied in metabolic research involving satiation signaling, food-intake regulation, gastric-motility pathways, post-meal glucagon signaling, and body-composition endpoints. Available as 5 mg or 10 mg per vial, with 10 vials per kit. Not an approved medicine; for laboratory research use only.
Eloralintide works through the amylin pathway rather than the GLP-1 pathway. Endogenous amylin is a 37-amino-acid hormone co-secreted with insulin after nutrient intake. Amylin receptors are complexes formed by the calcitonin receptor (CTR) and one of three receptor-activity-modifying proteins (RAMP1, RAMP2, or RAMP3), producing AMY1R, AMY2R, and AMY3R.
Preferential AMY1R activation: AMY1R is the CTR-RAMP1 receptor complex. In the published discovery study, eloralintide acted as a full agonist in cyclic-AMP assays and was reported to be approximately 12-fold more potent at human AMY1R than at human CTR and approximately 11-fold more potent at human AMY1R than at human AMY3R. “Preferential” does not mean exclusive: receptor response can vary with receptor composition, expression level, assay design, and concentration.
Pathways studied: amylin-receptor signaling is associated with satiation and meal termination, gastric-motility regulation, post-meal glucagon signaling, and energy-balance endpoints. In preclinical rat studies reported during discovery, eloralintide reduced food intake and body weight in a dose-dependent manner, with the weight change predominantly attributed to fat mass. These are model-specific findings and are not treatment claims.
Development status: published phase 1 and 48-week randomized phase 2 studies have evaluated once-weekly investigational eloralintide in adults with overweight or obesity. The compound remains in clinical development and is not an approved medicine. Clinical-trial results refer to the sponsor's investigational drug product and do not validate this research material for human use.
Key published records: discovery and receptor pharmacology, DOI 10.1016/j.molmet.2025.102271; phase 1 study, DOI 10.1111/dom.70439; phase 2 study, DOI 10.1016/S0140-6736(25)02155-5 and ClinicalTrials.gov NCT06230523.
This product is supplied as a lyophilized powder. Unopened vials can be stored at room temperature for up to 2 years when kept sealed, dry, and protected from light. Avoid excessive heat, moisture, and repeated temperature changes during storage.
After reconstitution, store the solution at 2-8°C, protected from light, and use it within 30 days. Label the vial with the reconstitution date. Use sterile handling, avoid vigorous shaking and repeated freeze-thaw cycles, and do not use the material if the seal is damaged or if persistent particles, unexpected cloudiness, or discoloration is present after dissolution.
Eloralintide, also called LY3841136, is an investigational long-acting synthetic amylin analog designed to preferentially activate AMY1R. It is not an approved medicine and is offered here only as a laboratory research material.
Eloralintide activates amylin receptors, with published in-vitro data showing a preference for human AMY1R. AMY1R is a receptor complex made from the calcitonin receptor and RAMP1. Activation is studied through cyclic-AMP signaling and downstream endpoints related to satiation, gastric motility, food intake, post-meal glucagon signaling, and energy balance.
No. Eloralintide is an amylin-receptor agonist and does not belong to the GLP-1 receptor agonist class. Both pathways are studied in metabolic research, but they use different receptors and should not be treated as interchangeable.
It means eloralintide showed greater potency at human AMY1R than at the comparator human CTR and AMY3R receptors in the published discovery assays. It does not mean the molecule can activate only AMY1R, and it does not predict the response of every experimental model.
Eloralintide has been evaluated in published phase 1 and phase 2 clinical studies and remains in clinical development. Those studies do not make this product an approved medicine and do not validate commercial research vials for human use.
The product is supplied as lyophilized powder in either 5 mg per vial or 10 mg per vial. Each kit contains 10 vials.
Keep unopened vials sealed, dry, and protected from light at room temperature for up to 2 years. After reconstitution, store at 2-8°C, protected from light, and use within 30 days. Avoid vigorous shaking and repeated freeze-thaw cycles.
No. This product is intended only for controlled laboratory research. The information on this page is not dosing, treatment, or medical guidance.
Contact our online support for real-time communication about products, orders, shipping, payment, or bulk supply.
